Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
124.38
-0.06 (-0.05%)
Nov 20, 2024, 4:00 PM EST - Market closed
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 57.83M EUR in the quarter ending September 30, 2024, with 20.40% growth. This brings the company's revenue in the last twelve months to 327.43M, up 115.54% year-over-year. In the year 2023, Ascendis Pharma had annual revenue of 266.72M with 421.20% growth.
Revenue (ttm)
327.43M EUR
Revenue Growth
+115.54%
P/S Ratio
19.44
Revenue / Employee
372,499 EUR
Employees
879
Market Cap
7.43B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
Dec 31, 2022 | 51.17M | 43.40M | 557.93% |
Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
Dec 31, 2019 | 13.38M | 2.79M | 26.41% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Walgreens Boots Alliance | 147.66B |
Bausch + Lomb | 4.68B |
The Ensign Group | 4.11B |
Jazz Pharmaceuticals | 3.99B |
Bruker | 3.24B |
Chemed | 2.38B |
Repligen | 633.51M |
Legend Biotech | 520.18M |
ASND News
- 6 days ago - Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Ascendis Pharma Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency - GlobeNewsWire
- 7 weeks ago - New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024 - GlobeNewsWire
- 2 months ago - Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs - GlobeNewsWire
- 2 months ago - Ascendis Pharma A/S Announces Proposed Public Offering of ADSs - GlobeNewsWire
- 2 months ago - Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year - Benzinga
- 2 months ago - Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo - GlobeNewsWire